

**Datasheet for 600-401-FZ0****WIPI1 Antibody****Overview**

<b>Description:</b>	Anti-WIPI1 (RABBIT) Antibody - 600-401-FZ0
<b>Item No.:</b>	600-401-FZ0
<b>Size:</b>	100 µg
<b>Applications:</b>	ELISA, IF, WB
<b>Reactivity:</b>	Human, Mouse, Rat
<b>Host Species:</b>	Rabbit

**Product Details**

<b>Background:</b>	WIPI1 (WD repeat domain, phosphoinositide interacting-1), also known as WIPI1, ATG18 or WIPI49, is thought to play a role in autophagy and may regulate protein trafficking in certain recycling pathways. It contains three WD repeats and has a 7-bladed propeller structure with a conserved motif that facilitates its interaction with other proteins. WIPI1 localizes to cytoplasmic vesicles, endosomes, clathrin-coated vesicles and the trans-Golgi network. It is ubiquitously expressed with highest expression in heart, testis, placenta, pancreas and skeletal muscle. WIPI1 is upregulated in a variety of tumors, suggesting a role in carcinogenesis.
<b>Synonyms:</b>	WIPI1 Antibody, ATG18, ATG18A, WIPI49, WD repeat domain phosphoinositide-interacting protein 1, Atg18 protein homolog, WIPI-1
<b>Host Species:</b>	Rabbit
<b>Clonality:</b>	Polyclonal
<b>Format:</b>	IgG

**Target Details**

<b>Gene Name:</b>	WIPI1
<b>Reactivity:</b>	Human, Mouse, Rat
<b>Immunogen Type:</b>	Conjugated Peptide
<b>Immunogen:</b>	Anti-WIPI1 antibody was prepared from whole rabbit serum produced by repeated immunizations with a 17 amino acid synthetic peptide near the C-terminus of human WIPI1.

**Purity/Specificity:** Anti-WIP1 Antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography. At least two isoforms of WIP1 are known to exist; this antibody will detect both isoforms.

**Relevant Links:**

- [UniProtKB - Q5MNZ9](#)
- [GeneID - 55062](#)
- [NCBI - NP\\_001307701.1](#)

## Application Details

**Tested Applications:** ELISA, IF, WB

**Application Note:** Anti-WIP1 Antibody has been tested for use in ELISA, Western Blotting and Immunofluorescence. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 49 kDa in Western Blots of specific cell lysates and tissues.

**Assay Dilutions:** All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

**ELISA:** 1:10,000 - 1:20,000

**IF:** 20 µg/mL

**WB:** 1-2 µg/mL

## Formulation

**Physical State:** Liquid (sterile filtered)

**Concentration:** 1 mg/mL by UV absorbance at 280 nm

**Buffer:** 0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2

**Preservative:** 0.02% (w/v) Sodium Azide

**Stabilizer:** None


## Shipping & Handling

**Shipping Condition:** Dry Ice

**Storage Condition:** Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

**Expiration:** Expiration date is one (1) year from date of receipt.

## Images




### Immunofluorescence Microscopy

Immunofluorescence of WIP1.

Tissue: human colon tissue.

Primary Antibody: WIP1 antibody at 20 µg/mL.



### Western Blot

Western blot analysis of WIP1.

Load: rat colon tissue lysate.

Primary Antibody: WIP1 antibody at (A) 1 and (B) 2 µg/mL.

## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.